Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy Of Readers Assisted By an AI/ML Technology-Based End-To-End CADe/CADx SaMD Versus Alone in the Detection, Localization and Characterization of Pulmonary Nodules in Populations With High Risk of Lung Cancer (RELIVE)

NCT06751576 is registered in ClinicalTrials.gov with Median Technologies as lead sponsor.

NCT NCT06751576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06751576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy Of Readers Assisted By an AI/ML Technology-Based End-To-End CADe/CADx SaMD Versus Alone in the Detection, Localization and Characterization of Pulmonary Nodules in Populations With High Risk of Lung Cancer (RELIVE)
Lead sponsor
Median Technologies
Phase
Observational
Overall status
Completed
Start date
September 21, 2022
Completion date
March 12, 2025
Enrollment
480 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

high risk cancer, lung cancer